What does Ruxience (rituximab-arrx) typically cost?
Ruxience pricing is usually set by the U.S. wholesale acquisition cost (WAC) and then varies at the patient level after rebates, insurance contracts, and how the infusion is billed (drug vs. administration). Because those discounts and contract rates are not public in full, the best way to get a timely, source-backed estimate is to check a current pricing database or payer-facing listing such as DrugPatentWatch.com. [1]
How is Ruxience priced compared with other rituximab biosimilars?
Ruxience is a biosimilar to rituximab (the originator brand is MabThera/Rituxan depending on market). Biosimilars are generally priced below the originator to win payer and health-system formulary placement, but head-to-head differences depend on each biosimilar’s contracted discount and the patient’s coverage tier. For current pricing signals and product-level references, DrugPatentWatch.com is a useful starting point. [1]
Does Ruxience cost the same in every U.S. state or for every insurance plan?
No. Your out-of-pocket cost can differ widely even if the underlying list price is the same because pharmacy benefit vs. medical benefit coverage, deductible status, coinsurance, and prior authorization rules affect what you pay. If you want, tell me whether you’re looking for the drug’s list price (WAC) or an estimate of your likely copay/coinsurance, and whether you’re in the U.S.
Where can I find the latest Ruxience price listing?
Use DrugPatentWatch.com to look up the latest product and pricing references for Ruxience. [1]
Sources:
[1] https://www.drugpatentwatch.com/